Core Insights - Medicus Pharma Ltd. announced promising results from its Phase 2 SkinJect® study, indicating an overall response rate (ORR) of 80% in the 200µg cohort at Day 57, suggesting that the majority of treated lesions may avoid surgery [2][9] - The company aims to address a significant unmet medical need in non-melanoma skin cancer, particularly basal cell carcinoma (BCC), which is the most common cancer worldwide [7][18] Group 1: Clinical Data and Analysis - The 200µg cohort demonstrated a 73% clinical clearance rate at Day 57, indicating that approximately three out of four treated lesions may achieve visual resolution, potentially allowing many patients to defer or avoid immediate surgical intervention [8][11] - The study showed continued improvement in clearance rates from Day 29 to Day 57, supporting the notion of a durable treatment effect [12] - The dataset is considered decision-grade, supporting regulatory engagement and potential business partnerships [14] Group 2: Expert Insights and Perspectives - Dr. Babar Rao, a key opinion leader in dermatology, will provide an independent clinical interpretation of the dataset during the upcoming conference call, emphasizing the clinical significance of the findings in the context of the broader BCC treatment landscape [4][5] - The findings highlight a significant treatment backlog in BCC, where patients may face delays or undergo unnecessary procedures [5] Group 3: Strategic Positioning and Future Plans - The company is entering a catalyst-rich period, with plans to refine histological clearance endpoints and engage in discussions with the FDA regarding the registrational study design [14] - Medicus is also focusing on optimizing clinical trial design and exploring co-development opportunities, including a collaboration with Helix Nanotechnologies for mRNA vaccine development [19][20] - The company aims to position SkinJect as a minimally invasive alternative to surgery, addressing a large and underserved BCC patient population [14][18]
Medicus Pharma Business Update Call to Highlight 80% Overall Response Rate (ORR) in Phase 2 SkinJect Study and Agentic AI-enabled Drug Development Plan